



Request for Prior Authorization
CHRONIC PAIN SYNDROMES

(PLEASE PRINT - ACCURACY IS IMPORTANT)

Form with fields for IA Medicaid Member ID #, Patient name, DOB, Patient address, Provider NPI, Prescriber name, Phone, Prescriber address, Fax, Pharmacy name, Address, Phone, Pharmacy NPI, Pharmacy fax, NDC.

Prior authorization is required for pregabalin (Lyrica®) and milnacipran (Savella™). These drugs will be considered for their FDA indication(s) and other conditions as listed in the compendia. Requests for doses above the manufacturer recommended dose will not be considered. The trial examples below are not an all inclusive list. Please refer to the Preferred Drug List (PDL) located at www.iowamedicaidpdl.com for a complete list of preferred drugs in these therapeutic classes. For patients with a chronic pain diagnosis who are currently taking opioids, as seen in pharmacy claims, a plan to decrease and/or discontinue the opioid(s) must be provided with the initial request. Initial authorization will be given for three (3) months. Requests for renewal must include an updated opioid treatment plan and documentation of improvement in symptoms and quality of life. Requests for non-preferred brand drugs, when there is a preferred A-rated bioequivalent generic product available, are also subject to the Selected Brand Name prior authorization criteria and must be included with this request. Payment will be considered under the following conditions:

Preferred (no PA required within quantity limit)

Non-Preferred

[] Duloxetine

[] Cymbalta

[] Lyrica

[] Savella

Strength

Dosage Instructions

Quantity

Days Supply

[] Fibromyalgia (Lyrica® or Savella™): A diagnosis of fibromyalgia with the following documented trials:

a) A trial and therapy failure at a therapeutic dose with gabapentin plus one of the following preferred generic agents: tricyclic antidepressant (amitriptyline, nortriptyline) or SNRI (duloxetine, venlafaxine er).

Gabapentin Trial Dose: Trial start date: Trial end date:

Reason for Failure:

Preferred Drug Trial #2 Name/Dose: Trial start date: Trial end date:

Reason for Failure:

b) Documented non-pharmacologic therapies (such as cognitive behavior therapies, exercise, etc.)

Non-Pharmacological Treatments Tried:

**Request for Prior Authorization-Continued
CHRONIC PAIN SYNDROMES**

(PLEASE PRINT – ACCURACY IS IMPORTANT)

Post-Herpetic Neuralgia (Lyrica®): A diagnosis of post-herpetic neuralgia with the following documented trials:
A trial and therapy failure at a therapeutic dose with gabapentin plus one of the following: tricyclic antidepressant (amitriptyline, nortriptyline), topical lidocaine, or valproate. .

Gabapentin Trial Dose: _____ Trial start date: _____ Trial end date: _____

Reason for Failure: _____

Preferred Drug Trial#2 Name/Dose: _____ Trial start date: _____ Trial end date: _____

Reason for Failure: _____

Diabetic Peripheral Neuropathy (duloxetine or Lyrica®): A diagnosis of diabetic peripheral neuropathy with the following documented trials:

A trial and therapy failure at a therapeutic dose with gabapentin plus one of the following: tricyclic antidepressant (amitriptyline, nortriptyline) or duloxetine.

Gabapentin Trial Dose: _____ Trial start date: _____ Trial end date: _____

Reason for Failure: _____

Preferred Drug Trial #2 Name/Dose: _____ Trial start date: _____ Trial end date: _____

Reason for Failure: _____

Partial Onset Seizures, as adjunct therapy (Lyrica®)

Neuropathic Pain associated with spinal cord injury (Lyrica®)

Other Diagnosis of Use: _____

Must complete for chronic pain diagnosis:

Initial Requests:

Does the member have current opioid use? Yes Name/Dose: _____ No

If yes, provide specific plan, including time line, to decrease and/or discontinue opioid use: _____

Renewal Requests:

Does the member have current opioid use? Yes Name/Dose: _____ No

If yes, provide updated opioid treatment plan: _____

Document improvement in symptoms and quality of life: _____

Other relevant information: _____

Attach lab results and other documentation as necessary.

Prescriber signature (Must match prescriber listed above.)	Date of submission
--	--------------------

IMPORTANT NOTE: In evaluating requests for prior authorization the consultant will consider the treatment from the standpoint of medical necessity only. If approval of this request is granted, this does not indicate that the member continues to be eligible for Medicaid. It is the responsibility of the provider who initiates the request for prior authorization to establish by inspection of the member's Medicaid eligibility card and, if necessary by contact with the county Department of Human Services, that the member continues to be eligible for Medicaid.